logo
logo

Splicebio Raises Eur 50M In Oversubscribed Series A Financing To Advance Protein Splicing Platform And Expand Gene Therapy Pipeline

Feb 16, 2022•over 3 years ago

Amount Raised

€50 Million

Round Type

series a

Barcelona

Description

SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing. The financing was co-led by UCB Ventures and existing shareholder Ysios Capital and joined by new investors New Enterprise Associates (NEA), Gilde Healthcare, Novartis Venture Fund, and existing shareholder Asabys Partners. The Company was seeded in 2020 by Ysios Capital and Asabys Partners.

Company Information

Company

Splice Bio

Location

Barcelona, Catalonia, Spain

About

SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. The Company's proprietary platform enables efficient delivery of large genes with adeno-associated vectors (AAV), overcoming the most fundamental challenge in the quest to curing a broad range of genetic diseases. SpliceBio's platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. For additional information, please visit www.splice.bio.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech